By contrast, blood sampling was much more accepted by this group of participants, suggesting that, as an alternative to CSF analyses, plasma levels of AD biomarkers should be used to confirm a diagnosis of MCI, although, until now, promising plasma biomarkers for AD (e.g., phosphorylated tau 217; p-tau217) have still been slightly less sensitive than CSF analyses and PET imaging [25]. Here, MAPT is linked to Alzheimer disease.